- Medical
indications for marijuana multiply
- Medical
marijuana (MMJ) market moves mainstream
- New
cannabis business unit to focus on MMJ market
Now that some 44 nations around the globe have passed laws
allowing marijuana for medical use, the market is set for rapid expansion in
the coming years. Industry analysts Grand View Research estimate that the
global medical marijuana market will reach a value of $55.8 billion by
2025, as the range of therapies for cannabis multiplies (http://ibn.fm/hHyKV). Much of
this expected demand will be driven by treatments for chronic pain, but
applications are also likely to be developed for a number of other ailments,
such as anxiety, epilepsy, multiple sclerosis (MS) and post-traumatic stress
disorder (PTSD), that appear to benefit from cannabis prescription. As a result
of these developments, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)
(FSE: 18H) has launched a medicinal cannabis division that will also advance
the company’s vision of becoming a global preventive health care company. The
new business unit will offer medical cannabis in a variety of forms, including
capsules, topical creams and transdermal patches, as well as through other
delivery methods.
There is a growing body of evidence that certain
disabilities and afflictions may benefit from cannabis medications. Conclusive
studies have demonstrated that intractable seizures caused by Dravet and
Lennox-Gastaut syndromes respond positively to CBD and that spasticity symptoms
in MS and chemotherapy-induced nausea may be alleviated with oral cannabinoids.
Moreover, the literature has identified a number of other indications for
cannabis therapies. These include disruptions in short term sleep resulting
from obstructive sleep apnea syndrome, fibromyalgia, chronic pain and multiple
sclerosis, as well as symptoms of Tourette syndrome, social anxiety disorders,
loss of appetite and weight associated with HIV/AIDS, and PTSD (http://ibn.fm/gsKvc).
The treatment of spasticity due to MS, with nabiximols, has
been the great success story of medical cannabis. Formulated and marketed under
the name of Sativex, it has been approved by regulatory authorities in 29
countries (http://ibn.fm/Y0HKF).
Nabiximols consists of the two main cannabinoids –
tetrahydrocannabinol (THC) and cannabidiol (CBD) – and is
administered with an oromucosal spray that delivers a dose of 2.7 mg THC
and 2.5 mg CBD.
PreveCeutical’s establishment of a cannabis division comes
on the heels of initiatives that it has already undertaken. In March 2018, the
company began shipping dried cannabis flower to UniQuest Pty. Ltd., its
research and development partner in Australia, which will analyze the
cannabinoid ‘fingerprints’. Cannabis contain more than 100 cannabinoids, as
well as other compounds like flavonoids and terpenoids, suggesting that its
putative activity is most likely derived from a combination of components
acting together. ‘Fingerprinting’ by chromatography, which examines the
composition ratio of the cannabinoids, is thus considered a superior method of
analysis.
After analysis, the cannabidiol features will be used as the
first therapeutic compound developed for the company’s Sol-gel nose-to-brain
drug delivery system. Formulation of an effective compound will follow initial
testing and is expected to require an additional 18 months. The company has
also begun a search for a compatible delivery device that patients will use to
apply Sol-gel. So far, at least one manufacturer has signed a letter of
non-disclosure to enable detailed discussions about its own device development
capabilities and compatibility with Sol-gel.
The Sol-gel technology, a brainchild of Dr. Harendra Parekh,
was developed at the University of Queensland, which has agreed to license it
to PreveCeutical. However, while the technology belongs to the University, its
application to infusion of cannabinoids will be covered by IP owned by
PreveCeutical. Parekh is Chief Research Officer of PreveCeutical. He also heads
the Drug/Gene Delivery Group at the Pharmacy Australia Centre of Excellence
(PACE) at the University of Queensland.
For more information, visit the company’s website at www.PreveCeutical.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment